At CC Diagnostics, we harness the power of medical advancements to improve the detection of cervical cancer. Our PCR-based reagent kit provide accurate and timely results, ensuring early intervention and better outcomes for patients.
Our cutting-edge technology allows for the early detection of cervical cancer, providing patients with a higher chance of successful treatment. With our innovative approach, we are able to identify abnormalities at the earliest stage, ensuring timely intervention and improved outcomes.
CC Diagnostics
At CC Diagnostics, we believe that early detection is key to improving patient outcomes. Our innovative medical advances are revolutionizing cervical cancer detection, providing accurate and timely results that can save lives.
Cervical cancer is the 4th most common cancer in women that leads to high morbidity and mortality. There is a global inequity in access to screening and treatment.
Each 4-week delay in diagnosis results in a 10% increase in mortality, significantly affecting womens health in a negative and clinically meaningful way.
Current participation of targeted women in cervical cancer screenings is only at 15% due to global inequities and associated emotional and physical barriers.
Current protocol requires multiple samples and works counterproductively. Most currently used screening and triage techniques are not compatible with automation.
Our Solution
Revolutionary screening technology detecting cervical cancer early using novel epigenetic markers.
🚀 CC Diagnostics & partners receive a €600K subsidy grant! Thanks to the support of Samenwerkingsverband Noord-Nederland (SNN) our team can further develop the Methica CC kit to solve the current challenges in cervical cancer screening. 🔬 With our trusted partners UMCG, MolGen and IQ Products we will bring molecular screening to the next level.
CC Diagnostics has successfully completed a large clinical validation study using samples from the Dutch National Screening Program. The results? **97% sensitivity for cancer detection**, outperforming the pap smear by **21%**—all without compromising specificity. This study, conducted across multiple centers, reflects real-world performance and eliminates bias, marking a significant leap forward in cervical cancer diagnostics.
🎉We’re thrilled to announce that CC Diagnostics was selected as one of 30 trailblazing European start-ups in the prestigious EIT Catapult! With this program's support, we’re more energized than ever to advance cervical cancer screening and make a global impact on women’s healthcare.
5 out of 5 stars